AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal

CinCor's hypertension drug misses primary endpoint in mid-stage study

CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study

The Year's First Three IPOs All Went 'Clunk.' This Is Why.

Three Biotech IPOs Started Trading. Here's How the Stocks Did.

CinCor Pharma's stock opens well above IPO price, then sells off sharply

CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range